PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast

Experimental and Molecular Pathology

Volumn 88, Issue 1, 2010, Pages 150-155

  Li, Hua ^a   Zhu, Rong ^a   Wang, Lei ^a   Zhu, Tengfang ^a   Li, Qiong ^b   Chen, Qi ^a   Wang, Hong ^b   Zhu, Hongguang ^a,b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Breast; Carcinoma in situ; Intraductal proliferative lesions; Mutation; PIK3CA

Indexed keywords

ARGININE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; GENOMIC DNA; GLUTAMIC ACID; GLYCINE; HISTIDINE; LYSINE; PHOSPHATIDYLINOSITOL 3 KINASE CATALYTIC ALPHA POLYPEPTIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOTRANSFERASE; PROGESTERONE RECEPTOR; THREONINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CELL ISOLATION; CONTROLLED STUDY; EXON; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATIONAL ANALYSIS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; MIDDLE AGED; MUTATION; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 74749101634     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2009.09.016     Document Type: Article

References (43)

1. Acconcia F., and Kumar R. Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett. 238 (2006) 1-14
2. Bader A.G., et al. Oncogenic PI3K deregulates transcription and translation. Nat. Rev., Cancer 5 (2005) 921-929
3. Balsara B.R., et al. Frequent activation of AKT in nonsmall cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25 (2004) 2053-2059
4. Broderick D.K., et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res. 64 (2004) 5048-5050
5. Byun D.S., et al. Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma. Int. J. Cancer 104 (2003) 318-327
6. Campbell R.A., et al. PI3kinase/AKT-mediated activation of estrogen receptor a: a new model for anti-estrogen resistance. J. Biol. Chem. 3 (2001) 9817-9824
7. Campbell I.G., et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64 (2004) 7678-7681
8. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 296 (2002) 1655-1657
9. Davies H., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
10. Dourdin N., et al. Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Cancer Res. 68 (2008) 2122-2131
11. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (1991) 403-410
12. Endersby R., and Baker S.J. PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene 27 (2008) 5416-5430
13. Eng C. PTEN: one gene, many syndromes. Hum. Mutat. 22 (2003) 183-198
14. Garami A., et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 11 (2003) 1457-1466
15. Gymnopoulos M., et al. Rare cancer-specific mutations in PIK3CA show gain of function. Proc. Natl. Acad. Sci. 104 (2007) 5569-5574
16. Hayes M.P., et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin. Cancer Res. 12 (2006) 5932-5935
17. Ikenoue T., et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 65 (2005) 4562-4567
18. Kang S., et al. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 802-807
19. Knobbe C.B., and Reifenberger G. Genetic alterations and aberrant expression of genes related to the PI3K/AKT signal transduction pathway in glioblastomas. Brain Pathol. 13 (2003) 507-518
20. Kwon C.H., et al. PTEN haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res. 68 (2008) 3286-3294
21. Lakhani S.R. The transition from hyperplasia to invasive carcinoma of the breast. J. Pathol. 187 (1999) 272-278
22. Leslie N.R., and Downes C.P. PTEN function: how normal cells control it and tumour cells lose it. Biochem. J. 382 (2004) 1-11
23. Levine D.A., et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin. Cancer Res. 11 (2005) 2875-2878
24. Li H., et al. Clonality analysis of intraductal proliferative lesions using the human androgen receptor assay. Neoplasma 54 (2007) 490-494
25. Maehama T., et al. PTEN and myotubularin: novel phosphoinositide phosphatases. Annu. Rev. Biochem. 70 (2001) 247-279
26. Martin M.B., et al. A role for AKT in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 141 (2000) 4503-4511
27. Min Y.H., et al. Constitutive phosphorylation of AKT/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 17 (2003) 995-997
28. Mommers E.C., et al. Balance of apoptosis and proliferation in the progression of preinvasive breast lesions. Breast Cancer Res. Treat. 58 (1999) 163-169
29. Mommers E.C., et al. Nuclear cytometric changes in breast carcinogenesis. J. Pathol. 193 (2001) 33-39
30. Morin P.J., et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275 (1997) 1787-1790
31. Pedrero J.M.G., et al. Frequent genetic and biochemical alterations of the PI3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int. J. Cancer 114 (2005) 242-248
32. Rajagopalan H., et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418 (2002) 934
33. Saal L.H., et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and HER2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 65 (2005) 2554-2559
34. Samuels Y., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
35. Samuels Y., et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7 (2005) 561-573
36. Sanchez R., et al. Diversity in the mechanisms of gene regulation by estradiol receptors. BioEssays 24 (2002) 244-254
37. Sansal I., and Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 22 (2004) 2954-2963
38. Tavassoli F.A., et al. Intraductal proliferative lesions. In: Tavassoli F.A., and Devilee P. (Eds). Pathology and Genetics of Tumors of the breast and Female Genital organs (2003), IARC Press, Lyon 63-73
39. van Diest P.J. Ductal carcinoma in situ in breast carcinogenesis. J. Pathol. 187 (1999) 383-384
40. Viacava P., et al. Different proliferative patterns characterize different preinvasive breast lesions. J. Pathol. 188 (1999) 245-251
41. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev., Cancer 2 (2002) 489-501
42. Wishart M.J., and Dixon J.E. PTEN and myotubularin phosphatases: from 3-phosphoinositide dephosphorylation to disease. Trends Cell Biol. 12 (2002) 579-585
43. Zhang H., et al. Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells. Breast Cancer Res. Treat. 112 (2008) 217-227